



Ref. No.: EIKO/BSE/2023-24/46

Date: 01st January, 2024

To,
Corporate Services Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.
Scrip Code: 540204

Dear Sir/ Ma'am,

Sub: Revision of Call Money Period for First and Final Call - intimation as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations ,2015

Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, we wish to inform you that the Company has considered and approved the revision of Call Money Payment Period for its First and Final Call as below:

Call Money Period begin date: 03rd January, 2024

Call Money Period end date: 17th January, 2024

Other than the above, all other terms and conditions as specified in Call Money Notice dated 26th December, 2023 remains the same

This is for your information and records.

Thanking You,

Yours Faithfully,

For Eiko Lifesciences Limited

Jaid Ismail Kojar
Chief Financial Officer

EIKO LIFESCIENCES LIMITED

CIN: L65993MH1977PLC258134;

Registered Office: 604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate, Thane-400604, Maharashtra, India; Contact Details: +91 77159 54966; Email-ID:

investor.relations@eikolifesciences.com ; Website: www.eikolifesciences.com

CORRIGENDUM TO THE CALL MONEY NOTICE

This Corrigendum is with reference to the Call Money Notice dated 26th December, 2023 dispatched to shareholders in relation to the First and Final Call of 31.50/- (Rupees Thirty-One and Fifty Paise Only) for 55,44,178 Partly Paid-up Equity Shares having Face Value of Re. 10/- issued by the Company, on a rights basis. The Shareholders may note the following modifications and corrections to the Call Notice with respect to Revision in Payment Period:

	From	To
Call Payment Period	Wednesday, 03rd January, 2024	Wednesday, 17th January, 2024

The Call Money Notice shall be read in conjunction with this Corrigendum and the Call Money Notice stands suitably modified to the extent of information set out above. The information in this Corrigendum supersedes the information in the Call Money Notice to the extent inconsistent with the information in Call Money Notice. Other terms and conditions provided in the Call Money Notice remain the same.

For Eiko Lifesciences Limited

Sd/-

Jaid Kojar

Chief Financial Officer

Place: Thane

Date: 01st January, 2024